Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …

The BCl-2 family has long been identified for its role in apoptosis. Following the initial
discovery of BCL-2 in the context of B-cell lymphoma in the 1980s, a number of homologous …

Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …

Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in
multiple myeloma (MM) cells, particularly in those harboring t (11; 14), which express high …

New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-
Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to …

BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

Defects in apoptotic cell death can promote cancer and impair responses of malignant cells
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by keeping the cell …

Deregulation of the BCL2 gene family plays an important role in the pathogenesis of acute
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …

Background Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces
apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has …